The recent acquisitions of Spark Therapeutics and Nightstar Rx signals the race to acquire gene therapy delivery platforms is well underway.

In the aftermath of the purchases, the few remaining validated platforms left on the market are looking like attractive buys. With the leaders of the field quickly being snapped up, the valuations of other gene therapy companies rose on the release of the news.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ripe for gene therapy acquisition

Biotech companies bluebird bio, UniQure and Sangamo Therapeutics are targets for acquisition, in addition to the growing array of CRISPR-focused companies such as Editas Medicine and CRISPR Therapeutics.

Despite a small rally at the start of the year, the US biotech index still looks relatively cheap compared to the start of 2018.

Gene therapy is in vogue

In vivo gene therapy, the process of delivering genetic material into the body to cure disease has the potential to cure millions suffering from genetic conditions such as cystic fibrosis or muscular dystrophy. But the field is littered with failures: historically, delivery has proved to be the challenging roadblock to successful therapy.

Yet, the pharmaceutical world has been watching recent developments with interest. Renewed faith was rekindled by the Novartis acquisition of gene therapy company AveXis Therapeutics in April 2018 for $8.7 billion.

Suddenly, after years of looking like a risky proposition, gene therapy is now very much in vogue. Large pharmaceutical companies are racing to acquire the few validated delivery platforms under development – and many have a serious fear of missing out.

Gene therapy acquisitions: a potential sign of company value

In February, Swiss-based Roche acquired gene therapy biotech Spark Therapeutics for $4.8 billion. Late stage Haemophilia A and B candidates (SPK-8001 & SPK-9011) from Spark had proven successful in late-stage trials. Roche will use these to expand its offering in haemophilia and is likely to use the Spark core delivery platform for approaches that target the liver.

Success has also arrived for Nightstar Therapeutics, acquired by Biogen for $800 million in the last week. The Nightstar lead candidate, NSR-REP1 for choroideremia, had received Regenerative Medicine Advanced Therapy Designation by the US Food and Drug Administration and the company announced expansion into a Phase 2/3 study in November 2018. Biogen is likely to use the Nightstar platform in the development of other products in ophthalmology.

The winter is almost over – and now gene therapy looks set for spring.